Analytik NEWS
Online Laboratory Magazine
02/05/2023

01/20/2023

Promising active ingredient to combat multi-resistant bacteria

Share:


The hospital pathogen Pseudomonas aeruginosa requires the sugar-binding proteins LecA and LecB to form biofilms as well as to attach to and penetrate host cells. These so-called lectins are therefore suitable targets for active substances to combat Pseudomonas infections.

Researchers from Saarbrücken and Freiburg have now produced potent inhibitors for LecA and LecB that are more stable and soluble than previous drug candidates. These optimized molecules have been tested in virulence assays and show promising properties for the development of new drugs.

Pseudomonas aeruginosa is a Gram-negative bacterium that belongs to the group of highly antibiotic-resistant and clinically relevant ESKAPE pathogens. According to the World Health Organization (WHO), it is one of the critical priority pathogens because it is often resistant to antibiotics and lacks treatment options. P. aeruginosa produces two lectins, LecA and LecB, which it uses to bind to sugar molecules.

It requires them for adhesion to host cells and for biofilm formation - two properties that are critical to the bacterium's pathogenicity. This makes these lectins promising targets for synthetic agents that counteract the bacterium's disease-causing properties and bypass its antimicrobial resistance.

Prof Alexander Titz's research group at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Saarland University is investigating molecules to inhibit bacterial lectins, particularly from P. aeruginosa. HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University. The group, which is also part of the German Center for Infection Research (DZIF), had already developed highly potent LecA inhibitors, but they had low water solubility and limited stability, which prevented their further biological analysis.

The current results come from a joint research project with Prof Winfried Römer's group at the University of Freiburg and the Cluster of Excellence CIBSS - Centre for Integrative Biological Signalling Studies. Römer and his team are investigating how the lectins LecA and LecB of P. aeruginosa influence physiological processes such as immune response and wound healing, and how this can be prevented by inhibitors.

The researchers have now succeeded in significantly improving the chemical properties of previous lectin inhibitors. The targeted modification of linker regions within the molecules increased their solubility by a factor of 1000 and enhanced their chemical and metabolic stability. The results of the collaborative project have been published as a "hot paper" in the renowned journal Angewandte Chemie.

The greatly increased solubility of the lectin inhibitors made it possible to evaluate their biological effect in cell-based assays. "We investigated the influence of the inhibitors on the biological function of LecA and the invasiveness of P. aeruginosa," Römer explains. "We were able to show that even relatively low concentrations of the LecA inhibitor are sufficient to prevent P. aeruginosa from invading host cells."

Thus, the inhibitors effectively block the binding of LecA to human cells. "In addition to these positive results in the cell assays, we also saw that the new inhibitor can be detected in urine for a long time, potentially opening up further treatment options for urinary tract infections," said Titz, head of the Chemical Biology of Carbohydrates research group at HIPS.

These results show that the developed drug candidates have the potential to circumvent antibiotic resistance of dangerous pathogens. In particular, inhibition of LecA-mediated virulence offers a promising starting point for new agents to treat often highly problematic infections with P. aeruginosa. The current results are a first step and open the door for the future development of new treatment options.

» Original publication

Source: Helmholtz Centre for Infection Research (HZI)